Journal of Medicine
Novartis Kisqali shows superior survival rates to AstraZeneca’s Faslodex in advanced breast cancer
December 12, 2019Business Services Journal of Medicine, Novartis, menopause
Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …
